Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.30 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135946 | 0.73 | MAPK1 (0.57) | MAPK1AXLDAO | |
| SCHEMBL16475105 | 0.73 | MAPK1 (0.57) | MAPK1AXLDAO | |
| SCHEMBL20118242 | 0.71 | MAPK1 (0.56) | MAPK1AXLGPR84CCNT1PIM1 | |
| SCHEMBL30828747 | 0.71 | MAPK1 (0.56) | MAPK1AXLGPR84PIM1ROCK2 | |
| SCHEMBL10072161 | 0.71 | MAPK1 (0.56) | MAPK1AXLGPR84PIM1HASPIN | |
| SCHEMBL25299939 | 0.71 | MAPK1 (0.56) | MAPK1AXLPRKCIADRA2AGPR84 | |
| SCHEMBL31150717 | 0.71 | MAPK1 (0.56) | MAPK1AXLPRKCIADRA2AGPR84 | |
| SCHEMBL4878480 | 0.71 | MAPK1 (0.56) | MAPK1AXLADRA2AGPR84 | |
| SCHEMBL18330446 | 0.69 | MAPK1 (0.52) | MAPK1AXL | |
| SCHEMBL22941145 | 0.69 | MAPK1 (0.52) | MAPK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250002518-A1 | SYNTHESIS OF HETEROARYNES AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-01-02 | — | — | US | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARAMCEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
| EP-4244224-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2023-09-20 | — | — | EP | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| WO-2009152087-A1 | BICYCLIC HETEROARYL COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152087-A1 | BICYCLIC HETEROARYL COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | MAPK1 306/4885AXL 2513/4885PRKCI 483/4885 |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | MAPK1 444/4885AXL 647/4885PRKCI 2522/4885 |
| US-20250002518-A1 | SYNTHESIS OF HETEROARYNES AND USE THEREOF | PARN, PAICS, PARG | MAPK1 2992/4885AXL 2784/4885PRKCI 4763/4885 |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | MAPK1 61/4885AXL 4214/4885PRKCI 145/4885 |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | MAPK1 79/4885AXL 219/4885PRKCI 64/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | MAPK1 444/4885AXL 647/4885PRKCI 2522/4885 |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | MAPK1 444/4885AXL 647/4885PRKCI 2522/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | MAPK1 397/4885AXL 518/4885PRKCI 2697/4885 |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKACA, KIT, FLT3 | MAPK1 143/4885AXL 456/4885PRKCI 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.